A Hold recommendation has recently been issued to pharmaceutical company Alnylam Pharmaceuticals, Inc. (ALNY) by Zacks senior pharmaceutical industry analysts Grant Zeng, CFA and Varun Parwal. Here's what their latest update had to say:
'Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi technology. The company possesses a deep, but very early-stage therapeutic pipeline. Merck's (MRK) billion-dollar acquisition of Sirna and the recent multi-million-dollar Alnylam Roche(RHHBY) deal provide an insight into the revenue potential the RNAi technology holds.
'We would like to remind investors that with just one candidate in clinical stage development, we are hesitant to project any product related revenues for Alnylam before 2010. We do not believe investors should pay for therapeutic candidates in early stages of clinical development. There are far too many development risks before we can assume Alnylam can commercialize anything using the technology.
'Valuation is difficult. We value Alnylam using relative valuation metrics. We come up with a $36 price target with a market cap of $1.4 billion.'
Read the full analyst report on ALNY.
Read the full analyst report on MRK.
Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all todays Analyst Blog entries on Zacks.com.